Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
about
Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort studyCandidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile.HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center.Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy.Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.FDG-PET imaging in hematological malignanciesFDG PET/CT imaging as a biomarker in lymphoma.The new therapeutical scenario of Hodgkin lymphoma.XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.Novel agents for the treatment of Hodgkin lymphoma.Risk-adapted strategies for the treatment of Hodgkin lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.Diagnostic yield of EBUS-TBNA for lymphoma and review of the literature.Understanding the information needs of people with haematological cancers. A meta-ethnography of quantitative and qualitative research.Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Hodgkin Lymphoma Mimicking Osteomyelitis.Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma.No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.The role of FDG-PET in Hodgkin lymphomaReal-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.The management of hodgkin lymphomas in pregnancies.Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.Interim FDG-PET in lymphoma, a questionable practice in hematology.Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages.Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.Cardiogenic Shock during First Infusion of Anthracycline Chemotherapy in a Patient with Hodgkin Lymphoma: An Unusual Event.
P2860
Q33578319-F8647DA0-A800-4504-BC92-B595ACB86421Q33671281-B3EFC9C6-2574-4D40-8A98-967D3F691414Q35694050-32CF1CBC-3A6D-42A6-ACC4-ACABC18535A3Q36073717-7EF3B971-8D05-41A4-9303-DCAA2A77B5CEQ36337603-D471C52E-2F5D-4F02-AE0C-288718E66651Q37149757-163455D7-E6E6-4322-8313-6AC6ECE7CDBAQ37178329-1BA8822E-FF74-4327-832E-C52E16669D5CQ37563122-8800E41A-1C13-4ED1-81E7-25898FB642A8Q37632114-5D854836-7910-4C53-AA2B-99CAD445212CQ38312367-38E69854-6BB0-40F2-8B0B-FA63E3F2946AQ38513816-C88628DF-C37E-4924-954B-B37966FF68F8Q38524029-AFCBCCE3-711E-44DE-81AB-5D7933B76327Q38549745-5ACC5241-DBE6-4AF8-919D-26E34A0553FAQ38581830-FC269B0D-22DC-4D31-8A21-F5CFE39543EDQ38591137-53DFC0F5-BA6E-4A5D-9A91-10508885A64CQ38664909-41C674D0-9BD6-47D4-8544-E0C5051B6294Q38680358-D5573309-1FB6-45A4-B78F-E787675CC2F0Q38700459-D858E261-EF58-4EDB-8372-AC3CA5482C0FQ38776129-C92BC1A0-A47C-4328-A367-670C332C734EQ38777496-60E05F4B-0080-4751-9D2E-5F8831BD39CFQ38786377-95232994-64F2-4C90-AAC6-158398CED9A2Q38792217-D214D341-B492-4F96-8884-6CDD7522D5B3Q38815516-C08326CD-54ED-4969-BE83-C69E8BCA26A8Q38819199-4A2B69AE-042F-423A-90CE-C2B30B2C8542Q39129451-64D96403-57D1-4A35-9C1A-70588E61B5AAQ39132041-5EA7173A-E022-4D38-B554-4C95AA7BC46CQ39324849-38F2CA3E-A44B-40B7-9756-381F671CA29EQ39728290-F62201B7-5CBE-46B9-A52B-877AABAB0E5BQ40040274-DB9FBEDE-D9B1-404D-AB54-2304D91546E8Q40142429-98CFEBEE-D84B-4C3B-9D10-DFF6371C8B53Q40588449-EFC1C056-7810-4E85-9241-CD4CE4C84940Q40929122-079C8311-4ED3-4B36-B002-BE5CCA5AC280Q41691698-C4F4D851-1411-4857-9913-25845932323AQ47768771-C1E5B879-6D60-4D43-911D-33AB2EED2D24Q48162570-293BB095-4B15-4B79-8784-FB38577D8700Q48287544-8A610EE4-7929-4E2A-922D-E82F19C7F357Q48316502-0AE2F087-AFE0-40A5-938B-FE50346039A0Q48890938-9959FBAE-1EA3-4F97-A42D-8C8D13B0D472Q50044569-AF88F43F-1233-47E7-A285-C858FA65934DQ50081496-B5B13BA2-3CC4-422D-9AC1-2299905747C8
P2860
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@ast
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@en
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@nl
type
label
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@ast
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@en
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@nl
prefLabel
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@ast
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@en
Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.
@nl
P2093
P2860
P50
P356
P1433
P1476
Hodgkin's lymphoma: ESMO Clini ...... nosis, treatment and follow-up
@en
P2093
D A Eichenauer
ESMO Guidelines Working Group
P2860
P304
P356
10.1093/ANNONC/MDU181
P478
25 Suppl 3
P577
2014-07-25T00:00:00Z